文献速递医学教育与科研方法流行病学与生物统计

临床试验主要结果论文中卫生系统数据使用报告的系统评价

The reporting of health systems data use in primary results publications of clinical trials: a systematic review.
PubMed 文献 · Trials · 2025-11-26

该系统评价纳入46项试验的49篇主要结果论文,评估2017至2018年间获取卫生系统数据(HSD)的试验在主要结果发表中对HSD使用的报告情况。结果显示无一篇论文报告CONSORT-ROUTINE扩展所建议的全部信息,但自该指南发布后HSD使用报告有所改善。

要点

  • 纳入46项试验的49篇主要结果论文,评估HSD使用报告。
  • 无一篇论文报告CONSORT-ROUTINE扩展建议的全部信息。
  • 自CONSORT-ROUTINE指南发布后,HSD使用报告有所改善但未达预期。

核心结论

  • HSD使用报告随时间有所改善,但仍未达到CONSORT-ROUTINE扩展所设定的期望。

研究设计与样本

  • 系统评价,基于Lensen等(Trials 21(1):398, 2020)识别的90项试验,纳入已发表主要结局结果的试验,最终纳入46项试验的49篇主要结果论文。
  • 通过ISRCTN、ClinicalTrials.gov、EU临床试验注册库、PubMed和Embase识别合格论文,将HSD使用报告与CONSORT-ROUTINE扩展的期望进行比较。

主要发现

  • 总体而言,无一篇纳入论文报告CONSORT-ROUTINE建议的全部信息。
  • 自CONSORT-ROUTINE指南发布后,HSD使用报告有所改善。

临床怎么用

  • 作者建议应鼓励试验者按照CONSORT-ROUTINE扩展指南在论文中提供关于HSD使用的进一步信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data collected within clinical trials often overlaps with routinely collected Health Systems Data (HSD). There is potential for HSD to reduce burdens for trials and understanding HSD use can help triallists make decisions about using HSD in future trials. However, it is unknown to what extent HSD use has been reported in trial publications, despite the development of guidelines such as ESMO-GROW and CONSORT-ROUTINE extension for reporting HSD use in trials. This study expands on work previously conducted by Lensen and colleagues (Trials 21(1):398, 2020). It aims to provide insights into how HSD use is reported in main result publications that present main trial results, before and after the release of the CONSORT-ROUTINE extension. METHODS: This was a systematic review of the reporting of HSD use in primary results publications of trials that accessed HSD between 2017 and 2018. Of 90 trials identified by Lensen and colleagues, those that had published primary outcome results were included in the review. Trials were excluded if (1) primary results were not yet due to be reported; (2) not yet published; (3) they were published prior to June 2017; (4) they were published in 2017, but HSD was accessed in 2018 and (5) the primary publication only reported HSD use in secondary, interim or Study Within a Trial (SWAT) analysis. Eligible publications were identified using ISRCTN, ClinicalTrials.gov, EU Clinical Trials Registries, PubMed and Embase. The reporting of HSD use was compared against expectations for reporting outlined in the CONSORT-ROUTINE extension. RESULTS: Forty-nine primary publications from 46 trials were included in the review. Overall, none of the included publications reported all the information suggested in the CONSORT-ROUTINE. However, there has been an improvement in the reporting of HSD use, since the publication of the CONSORT-ROUTINE guidelines. CONCLUSIONS: Reporting of HSD use has improved over time. However, it still does not meet the expectations set out in the CONSORT-ROUTINE extension. Triallists should be encouraged to provide further information in publications about the use of HSD as per the CONSORT-ROUTINE extension guidelines. This would allow greater transparency in reporting, facilitating effective HSD use in future trials.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Thompson J, Bobou M, Roberts K, et al. The reporting of health systems data use in primary results publications of clinical trials: a systematic review. Trials. 2025. PMID: 41299719. doi:10.1186/s13063-025-09227-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。